AVITA MEDICAL WKN: A0Q40S ISIN: AU000000AVH4 Kürzel: AVMXF Forum: Aktien Thema: Hauptdiskussion

Bald wird wieder zugeschlagen :)

https://www.wndu.com/content/news/Spray-on-skin-better-than-grafts-for-some-burns-564936092.html

Also ich bin zuversichtlich dass wir bald über 1$ sehen werden oder weit mehr aber was weiß man schon, hätte jetzt nicht gedacht dass es jetzt runter geht obwohl es gute Infos gibt. https://mynewscrunch.com/taking-a-look-at-the-data-behind-avita-medical-ltd-asx-avh/

to Support Commercial Growth and Pipeline Development

Ich lese gerade im Forum von Yahoofinanzen, die sind optimistisch drauf wundern sich wozu eigentlich avita sich dieses Investment von 120Millionen organisiert haben da sie auch ohne wunderbar gewachsen sind.

Ich glaube dass sind Trader die davon leben und er hat sich 60K gekauft https://www.wikifolio.com/de/de/w/wfwawesosu?utm_source=wallstreet-online&utm_medium=trending_wso&utm_content=topwfs&utm_campaign=singlestockbox&u=AU000000AVH4

Nö aber ich würde niemals irgendwo zuschlagen, was die letzten beiden Tage um gute 15% gefallen ist.

Hast du irgendwelche Infos

Erst bei 0,3 wieder :)

Bei dem Wert werde ich heute nachlegen

da ich letzte Woche verdoppelt habe bin ich jetzt etwas im Minus... aber die Richtung auf lange Sicht ist entscheidend.

Es ist und bleibt ein volatiler pennystock.

Puhh was ist den los, habe was anderes erwartet

ASX/News Release AVITA Medical Announces Institutional Placement of A$120.0 Million to Support Commercial Growth and Pipeline Development Valencia, Calif., USA, and Melbourne, Australia, 13 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today an institutional placement of A$120.0 million (Institutional Placement) to fund pipeline development of new indications, including optimizing support for clinical trials and development projects, as well as the Company’s continued U.S. commercial growth strategy. The Institutional Placement was managed by Bell Potter as sole lead manager. Cowen served as financial advisor to the Company in connection with the Institutional Placement. Lake Street Capital Markets also acted as a financial advisor to Avita Medical. The Company has received commitments for A$120.0 million at an issue price of A$0.59 per fully paid ordinary share, representing a 7.2 percent discount to the 30-day VWAP, and a 14.5 percent discount to the last closing price on 8 November 2019. The new AVITA shares to be issued under the Institutional Placement will rank equally with existing AVITA shares on issue. The Institutional Placement will occur in a single tranche, and issue 203,389,831 shares to international and Australian sophisticated investors under its 15 percent placement capacity (under ASX Listing Rule 7.1). “We are grateful for the confidence and conviction of the investors who have joined us in our mission to transform burn care with our revolutionary RECELL® System and to promptly execute on our pipeline of add-on indications,” said Dr. Mike Perry, Chief Executive Officer. “This financing reflects our shared excitement for, and strong confidence in, AVITA Medical’s myriad near-term growth opportunities. These include trauma/soft tissue reconstruction, vitiligo, our next generation RECELL device to facilitate use of the RECELL System in the outpatient setting, and pediatric scald wounds, as well as efforts to enable research programs to support the advancement and extension of our existing intellectual property. Through diligent and focused execution on our highly de-risked pipeline of new indications, we have the opportunity to access the full potential of our innovative regenerative medicine platform to advance patient care that addresses unmet medical needs, while aggressively growing our top *** revenues and ultimately building a robust self-sustaining business.” Accelerating pipeline development The funds from the Institutional Placement will enable AVITA Medical to fast-track progression of clinical development programs and to accelerate its broader commercialization strategy. Key initiatives include: • Initiating U.S. pivotal trials to establish the safety and efficacy of the RECELL System in soft tissue reconstruction and traumatic wounds, as well as early intervention in the treatment of pediatric scald wounds • Further development and submission to the FDA of a next generation RECELL System to facilitate access to the large outpatient market • Pilot studies with the RECELL System for the treatment of vitiligo, and subsequent rapid advancement into a pivotal clinical trial to secureadva this indication in the U.S. For personal use only

Ok top, danke 👍

eVo99 => weil Avita ins ASX200 rauf rutscht